PURPOSE: Occurrence of brain damage is frequently associated with abnormal blood-brain barrier (BBB) function. Two brain-specific proteins, S100beta and neuron-specific enolase (NSE) are released systemically in a variety of neurological diseases, but S100beta levels sometimes rise in the absence of neuronal damage, suggesting that S100beta is a marker of BBB rather than neuronal damage. METHODS: We measured both proteins in the serum of patients undergoing iatrogenic BBB disruption with intrarterial mannitol, followed by chemotherapy. RESULTS: Serum S100beta increased significantly after mannitol infusion (p<0.05) while NSE did not. Furthermore, in a model of intracerebral hemorrhage, S100beta increases in CSF did not lead to serum changes at a time when the BBB was intact. Modeling of S100beta release from the CNS suggested that low (<0.34 ng/ml) serum levels of S100beta are consistent with BBB opening without CNS damage, while larger increases imply synthesis and release from presumable damaged glia. CONCLUSIONS: Thus, S100beta in serum is an early marker of BBB openings that may precede neuronal damage and may influence therapeutic strategies. Secondary, massive elevations in S100beta are indicators of prior brain damage and bear clinical significance as predictors of poor outcome or diagnostic means to differentiate extensive damage from minor, transient impairment.
PURPOSE: Occurrence of brain damage is frequently associated with abnormal blood-brain barrier (BBB) function. Two brain-specific proteins, S100beta and neuron-specific enolase (NSE) are released systemically in a variety of neurological diseases, but S100beta levels sometimes rise in the absence of neuronal damage, suggesting that S100beta is a marker of BBB rather than neuronal damage. METHODS: We measured both proteins in the serum of patients undergoing iatrogenic BBB disruption with intrarterial mannitol, followed by chemotherapy. RESULTS: Serum S100beta increased significantly after mannitol infusion (p<0.05) while NSE did not. Furthermore, in a model of intracerebral hemorrhage, S100beta increases in CSF did not lead to serum changes at a time when the BBB was intact. Modeling of S100beta release from the CNS suggested that low (<0.34 ng/ml) serum levels of S100beta are consistent with BBB opening without CNS damage, while larger increases imply synthesis and release from presumable damaged glia. CONCLUSIONS: Thus, S100beta in serum is an early marker of BBB openings that may precede neuronal damage and may influence therapeutic strategies. Secondary, massive elevations in S100beta are indicators of prior brain damage and bear clinical significance as predictors of poor outcome or diagnostic means to differentiate extensive damage from minor, transient impairment.
Authors: T Ingebrigtsen; B Romner; S Marup-Jensen; M Dons; C Lundqvist; J Bellner; C Alling; S E Børgesen Journal: Brain Inj Date: 2000-12 Impact factor: 2.311
Authors: Assia Jaillard; Marc Hommel; Alison E Baird; Italo Linfante; Rafael H Llinas; Louis R Caplan; Robert R Edelman; Steven Warach Journal: Cerebrovasc Dis Date: 2002 Impact factor: 2.762
Authors: M Kapural; Lj Krizanac-Bengez; G Barnett; J Perl; T Masaryk; D Apollo; P Rasmussen; M R Mayberg; D Janigro Journal: Brain Res Date: 2002-06-14 Impact factor: 3.252
Authors: Nicole E Lopez; Michael J Krzyzaniak; Chelsea Blow; James Putnam; Yan Ortiz-Pomales; Ann-Marie Hageny; Brian Eliceiri; Raul Coimbra; Vishal Bansal Journal: J Neurotrauma Date: 2011-10-26 Impact factor: 5.269
Authors: Tatiana Falcone; Damir Janigro; Rachel Lovell; Barry Simon; Charles A Brown; Mariela Herrera; Aye Mu Myint; Amit Anand Journal: J Psychiatr Res Date: 2014-12-25 Impact factor: 4.791
Authors: Marcos G Lopez; Christopher G Hughes; Anthony DeMatteo; Jason B O'Neal; J Brennan McNeil; Matthew S Shotwell; Jennifer Morse; Michael R Petracek; Ashish S Shah; Nancy J Brown; Frederic T Billings Journal: Anesthesiology Date: 2020-03 Impact factor: 7.892
Authors: Zhiqun Zhang; Stefania Mondello; Firas Kobeissy; Richard Rubenstein; Jackson Streeter; Ronald L Hayes; Kevin K W Wang Journal: Transl Stroke Res Date: 2011-12-07 Impact factor: 6.829